Special Issue "Therapeutic Strategies Affecting MAPK-Oriented Interventions in Cancer"
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: 12 July 2024 | Viewed by 189
Interests: immunomodulators; innate immune defense; adaptive immunology; cell cycle check-point inhibitors; MAPK signaling; cancer chemoprevention
Special Issues, Collections and Topics in MDPI journals
Special Issue in Vaccines: Immunologic Mechanisms of Diabetic Ulcers
Mitogen-activated protein kinases (MAPKs) are protein kinases that play a key role in the transduction of extracellular signals to cellular responses that has implication in several types of cancer. Their mutated oncogenes turn normal cell phenotypes to become mesenchymal cancerous phenotypes. Therefore, research studies targeting the MAPK signaling and potential development of vaccines against these targets to impact the cancer immune environment are required. Studies involving future applications of immune-targeted vaccines as a cancer therapeutics implementing into clinical research are invited. Therefore, this Special Issue aims to give an overview to develop new strategies involving vaccines to treat cancer at the very early stages to improve survival. In this Special Issue plans to focus on the signaling pathways that can cause malignancy and identify not only chemo-preventive biomarkers but also valid targets for anticancer therapy. Hence, in this Special Issue, we invite and encourage high-quality original research and reviews.
Dr. Sunil Singh
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- identification of cancer prognostic biomarkers
- vaccines against cancers
- therapeutic strategies
- targets for anticancer therapy
- mechanism of actions
- adverse effects of targeting signaling
- effect on cancer patient’s survival rate